Tag Archives: endocarditis

Polyphor POL7080 And The Journey to The Land of Pyocyanea  (Part 2)

Posted on by — No Comments ↓

Roche’s current Phase 2 program is strangely ambiguous. RG-7929 has not made it into www.clinicaltrials.gov yet, only POL7080 is listed. An uncontrolled open label study in “patients with non-CF acute exacerbation of bronchiectasis due to P. aeruginosa requiring IV treatment” is enrolling. Well, good luck finding those patients! At best, Continue reading Polyphor POL7080 And The Journey to The Land of Pyocyanea  (Part 2)→

Most Anti-Infective Guidelines Don’t Get No Respect (Let Alone Use!)

Posted on by — No Comments ↓

It is no secret that most existing antibiotic guidelines are not getting much use these days.  The only indications pursued with any regularity are the feasible ones: ABSSSI, cUTI, and cIAI, much less CABP.  Yes, the occasional HABP/VABP trial is being undertaken by the intrepid but no company has taken Continue reading Most Anti-Infective Guidelines Don’t Get No Respect (Let Alone Use!)→

Adequate Penetration of Daptomycin Into Bone Tissue

Posted on by — No Comments ↓

After a single high dose of (8 or 10 mg/kg BW) of daptomycin IV, bone levels were measured in plasma and trabecular bone obtained during hip or knee surgery of 16 patients.[1] At the time of surgery, mean concentrations in plasma and synovial fluid were 39 and 22 µg/mL, respectively.  Continue reading Adequate Penetration of Daptomycin Into Bone Tissue→